Aim ImmunoTech reported a second quarter 2026 net loss of $3.8 million, or $0.43 per share, while significantly improving its liquidity position. The company transitioned into the second half of the year with $9.9 million in cash, supporting the advancement of its lead candidate, Ampligen, toward a pivotal Phase 3 study in metastatic pancreatic cancer.
Key Highlights
- Completed patient enrollment and Ampligen dosing in the DURIPANC Phase 2 study, with clinical benefit results anticipated in the first quarter of 2027.
- Cash and cash equivalents increased to $9.9 million as of June 30, 2026, compared to $3.0 million at the end of fiscal year 2025 following financing activities.
- Research and development expenses were reduced to $0.59 million for the quarter, down from $1.2 million in the prior year period, reflecting disciplined clinical spending.